Pluristem Therapeutics (PSTI) Downgraded by Zacks Investment Research

Share on StockTwits

Zacks Investment Research cut shares of Pluristem Therapeutics (NASDAQ:PSTI) from a hold rating to a sell rating in a research report released on Thursday morning, Zacks.com reports.

According to Zacks, “PLURISTEM THERAPEUTICS INC. is a bio-therapeutics company dedicated to the commercialization of non-personalized (allogeneic) cell therapy products for the treatment of several severe degenerative, ischemic and autoimmune disorders. The Company is developing a pipeline of products, stored ready-to-use, that are derived from the human placenta, a non-controversial source, and not from embryonic stem cells. “

Separately, Maxim Group restated a buy rating and set a $3.00 target price on shares of Pluristem Therapeutics in a research report on Wednesday, April 24th. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and three have issued a buy rating to the company. The company has an average rating of Hold and an average price target of $3.19.

Shares of PSTI opened at $0.64 on Thursday. The firm has a market cap of $93.06 million, a PE ratio of -2.56 and a beta of 1.13. Pluristem Therapeutics has a 1-year low of $0.50 and a 1-year high of $1.52.

In other Pluristem Therapeutics news, CEO Yaky Yanay bought 71,429 shares of the firm’s stock in a transaction that occurred on Monday, April 8th. The stock was bought at an average cost of $0.70 per share, for a total transaction of $50,000.30. Following the completion of the transaction, the chief executive officer now directly owns 4,253,045 shares of the company’s stock, valued at approximately $2,977,131.50. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Insiders own 6.70% of the company’s stock.

A number of hedge funds and other institutional investors have recently bought and sold shares of PSTI. Van ECK Associates Corp raised its position in shares of Pluristem Therapeutics by 38.7% in the fourth quarter. Van ECK Associates Corp now owns 50,443 shares of the biotechnology company’s stock worth $40,000 after acquiring an additional 14,087 shares during the period. Virtu Financial LLC raised its position in shares of Pluristem Therapeutics by 266.1% in the first quarter. Virtu Financial LLC now owns 85,104 shares of the biotechnology company’s stock worth $83,000 after acquiring an additional 61,858 shares during the period. Jane Street Group LLC raised its position in shares of Pluristem Therapeutics by 337.4% in the third quarter. Jane Street Group LLC now owns 94,023 shares of the biotechnology company’s stock worth $122,000 after acquiring an additional 72,526 shares during the period. ETF Managers Group LLC raised its position in shares of Pluristem Therapeutics by 49.6% in the fourth quarter. ETF Managers Group LLC now owns 250,848 shares of the biotechnology company’s stock worth $192,000 after acquiring an additional 83,207 shares during the period. Finally, Sumitomo Mitsui Trust Holdings Inc. acquired a new position in shares of Pluristem Therapeutics in the first quarter worth about $881,000. Institutional investors own 5.01% of the company’s stock.

Pluristem Therapeutics Company Profile

Pluristem Therapeutics Inc, together with its subsidiary, Pluristem Ltd., operates as a bio-therapeutics company in Israel. It focuses on the research, development, clinical trial, and manufacture of cell therapeutic products and related technologies for the treatment of various ischemic, inflammatory, and hematologic conditions, as well as autoimmune disorders.

Featured Story: What is Compound Interest?

Get a free copy of the Zacks research report on Pluristem Therapeutics (PSTI)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Pluristem Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pluristem Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.